diabetes glp-1 agonist Mechanisms of action of GLP-1RA Video: Non-insulin injectable antidiabetic drugs
Description
With such an eminent authority leading the experiments no one at the time thought to question the results
Amy Schroeder Principal Research Scientist | July 9, 2025 Current Landscape Overview Glucagon-like peptide-1 (GLP-1) receptor agonists (RAs) are an emerging drug class that are mostly indicated to improve glycemic control in patients with type 2 diabetes mellitus (T2D) and reduce body weight
Al-Karadsheh, T
Two randomized control clinical trials reported conflicting effects on bone mineral content (BMC) and bone mineral density (BMD): one trial demonstrated preservation of BMC with GLP-1 use, while the other found no significant difference in BMC or BMD between treatment and control groups
Switching between GLP1RAs should be individualised to mitigate known adverse effects, in particular, those gastrointestinal in nature
